Clinical trial
A Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 in Patients With DSM-IV-TR Schizophrenia
NCT01125358 is registered in ClinicalTrials.gov with Denovo Biopharma LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 in Patients With DSM-IV-TR Schizophrenia
- Lead sponsor
- Denovo Biopharma LLC
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- May 31, 2010
- Completion date
- September 30, 2012
- Enrollment
- 82 (actual)
- Sites
- 22
Conditions
As the registry lists them; a condition with its own page is linked.